Table 2.
Overview of surgical treatment planning for all included patients undergoing surgery between the 1 January 2018 and 31 December 2020
| 2018 (n = 13 985) | 2019 (n = 14 157) | 2020 (n = 12 154) | P‡ | |
|---|---|---|---|---|
| Time to surgery (days), median (i.q.r.) | ||||
| Overall | 36 (8–120) | 34 (6–109) | 28 (2–104) | <0.001§ |
| Oncological surgery | 33 (17–73) | 33 (17–76) | 33 (16–84) | 0.483§ |
| Non-oncological surgery | 71 (1–169) | 43 (1–144) | 2 (1–160) | <0.001§ |
| Not registered* | 3106 (22.2) | 3226 (22.8) | 2837 (23.3) | |
| Additional survey regarding delay to surgery | – | – | n = 8709 | |
| Surgical treatment postponed† | – | – | 839 (9.6) | |
| Oncological | – | – | 67 (0.8) | |
| Non-oncological | – | – | 772 (8.9) | |
| Reason for delay† | – | – | ||
| Capacity | – | – | 717 (8.2) | |
| (Suspected) COVID-19 infection | – | – | 53 (0.6) | |
| Other | – | – | 47 (0.5) | |
| Surgical treatment plan | ||||
| Oncological | n = 6260 | n = 6172 | n = 5712 | |
| Minimally invasive | 3724 (59.5) | 3803 (61.6) | 3519 (61.1) | 0.021 |
| Open | 1750 (28.0) | 1547 (25.1) | 1501 (26.0) | 0.001 |
| Local treatment | 246 (3.9) | 454 (7.4) | 347 (6.1) | <0.001 |
| Endovascular | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Unknown | 540 (8.6) | 368 (6.0) | 345 (6.0) | <0.001 |
| Non-oncological | n = 7725 | n = 7985 | n = 6442 | |
| Minimally invasive | 4720 (61.1) | 4876 (61.1) | 3719 (57.7) | <0.001 |
| Open | 586 (7.6) | 598 (7.5) | 543 (8.4) | 0.079 |
| Local treatment | 2 (0.0) | 2 (0.0) | 3 (0.0) | 0.724 |
| Endovascular | 1214 (15.7) | 1193 (14.9) | 1093 (17.0) | 0.007 |
| Unknown | 1202 (15.6) | 1313 (16.4) | 1084 (16.8) | 0.105 |
| Additional survey regarding changes to surgical treatment plan | – | – | n = 8700 | |
| Surgical treatment plan changed† | – | – | 149 (1.7) | |
| Reason for change in surgical approach | – | – | ||
| Capacity | – | – | 144 (1.7) | |
| COVID-19 infection | – | – | 0 (0) | |
| Protection of team | – | – | 1 (0.01) | |
| Other | – | – | 1 (0.01) | |
| Oncological neoadjuvant treatment plan | n = 6260 | n = 6172 | n = 5712 | |
| Received neoadjuvant treatment | 1429 (23.0) | 1392 (22.6) | 1450 (25.6) | 0.001 |
| Chemotherapy | 531 (8.8) | 555 (9.1) | 641 (11.3) | <0.001 |
| Radiotherapy | 170 (2.8) | 115 (1.9) | 105 (1.9) | 0.001 |
| Chemoradiotherapy | 738 (12.3) | 722 (11.8) | 704 (12.4) | 0.527 |
| Missing | 23 (0.4) | 50 (0.8) | 67 (1.2) | |
| Additional survey regarding changes to neoadjuvant treatment plan | n = 4428 | |||
| Neoadjuvant treatment plan changed† | 26 (0.6) | |||
| Other treatment | 4 (0.1) | |||
| Other scheme/dosing | 6 (0.1) | |||
| No therapy | 11 (0.3) | |||
| Other | 5 (0.0) | |||
Values are n (%) unless otherwise indicated.
*
Variable not registered in certain surgery-specific audits. An overview of registered variables that are available in only a selection of audits is provided in Table S1. Non-registered data were excluded from analyses. An overview of patient characteristics for each surgical audit is presented in Tables S2a–h. †As indicated in additional survey. ‡Pearson’s χ2 test, except §Mann–Whitney U test.